

CAPITAL INCREASE

Ambu A/S issued 770,000 warrants in 2015. Each warrant entitled the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 46 individuals participated in the 2015 scheme.

For the 2015 scheme the vesting period was three years, and the scheme could therefore be exercised in the trading window that opened on 9 November 2021 in connection with Ambu's Annual Report for 2020/21.

Since 9 November 2021, instructions have been received to exercise warrants as follows:

- 1 individual has issued instructions to exercise 5,000 warrants at the agreed exercise price of DKK 39.26 per share with a nominal value of DKK 0.50.

Today Ambu's Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of the Company's B shares will be increased by a nominal amount of DKK 2,500 from DKK 111,691,966 to DKK 111,694,466 through the issue of 5,000 Class B shares.

Following this and in consideration of the employees having left the company, no remaining warrants remain under the said 2015 scheme.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 23 November 2021 under the ISIN code of Ambu A/S' existing B shares (DK0060946788).

Under section 32 of the Danish Capital Markets Act, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

	Number of shares (nominal value DKK 0.50)	Nominal value (DKK)	Voting rights
A shares	34,320,000	17,160,000	343,200,000
B shares	223,388,932	111,694,466	223,388,932
Total	257,708,932	128,854,466	566,588,932

Contact

Michael Højgaard, CFO, miho@ambu.com / +45 4030 4349

Ambu A/S

Baltorpbakken 13, DK-2750 Ballerup, Denmark, Tel.: +45 7225 2000, CVR no.: 63 64 49 19, www.ambu.com

About Ambu

Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® Bag™ resuscitator and the Ambu® BlueSensor™ electrodes to our newest landmark solutions like the Ambu® aScope™ – the world's first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,500 people in Europe, North America and the Asia Pacific. For more information, please visit ambu.com.